TETON trials: Inhaled treprostinil lessens FVC decline in IPF at 52 weeks

Purpose-built for physicians

ORLANDO — Two replicate phase 3 trials have shown that adults with idiopathic pulmonary fibrosis had less FVC decline with 52-week inhaled treprostinil vs. placebo, according to a pair of presentations here.

In addition to being presented at the American Thoracic Society International Conference, these findings were simultaneously published in The New England Journal of Medicine.

“The results of TETON-1 validate what was seen in TETON-2,” Steven D. Nathan, MD, Schar Chair of the advanced lung disease and lung transplant program at Inova Fairfax Hospital, said in a press release. “The combined analysis provides an incredibly powerful dataset with both studies complementing each other well.”

In the multisite, double-blind, randomized, placebo-controlled phase 3 TETON-1 trial, Nathan and colleagues assessed 598 patients aged 40 years or older (mean age, 73 years; 77.3% men; 90.5% white; mean percentage of predicted FVC, 74.6%) with IPF in the U.S. and Canada to determine the impact of 52-week inhaled treprostinil (Tyvaso, United Therapeutics) on absolute FVC vs. placebo.